Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1220 results
May 2017
-
Media Release
Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients
Eight of nine evaluable patients tested had no signs of CLL in their bone marrow at three months.CTL119 is a humanized CD19-directed CAR-T cell therapy being developed in collaboration with the… -
Media Release
Novartis receives FDA approval for expanded use of Zykadia® in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC)
In ALK-positive metastatic NSCLC patients, Zykadia median progression-free survival (PFS) was 16.6 months, compared to 8.1 months with chemotherapy[1] The overall intracranial response rate… -
Media Release
Novartis' new analyses reinforce the potential of Ultibro® Breezhaler® for COPD patients historically treated with steroids
New analyses from the FLAME study suggest dual bronchodilator Ultibro® Breezhaler® provides similar or better efficacy versus steroid-containing therapies, regardless of blood eosinophil (a type of… -
Media Release
Novartis receives positive CHMP opinion for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)
Phase III trial, first-line treatment with Zykadia resulted in improved progression-free survival (PFS) over SOC chemotherapy with maintenance, including in patients with brain metastases[1]… -
Media Release
Novartis data at ASCO, ICML and EHA meetings demonstrate meaningful advancements in cancer care
Updated analyses from the Kisqali® pivotal Phase III MONALEESA-2 trial in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer to be… -
Media Release
Novartis Foundation and partners launch initiative to tackle hypertension and its root causes in low-income urban communities
Better Hearts Better Cities is a Novartis Foundation initiative to improve cardiovascular health in low-income urban communities by addressing the prevention, management and control of hypertension… -
Media Release
Novartis celebrates 21st annual Community Partnership Day with over 24,500 associates volunteering in their local communities
Community Partnership Day symbolizes the company's commitment to improving people's lives and serving our local communities Follow the excitement with #NovartisCPD2017 and #proudmoments2017 via… -
Media Release
Novartis exercises exclusive option agreement with Conatus for the treatment of NASH
Exclusive license for emricasan supports rapidly growing development portfolio in chronic liver diseases, including NASH Conatus has initiated the Phase IIb ENCORE-LF clinical trial with…
April 2017
-
Media Release
Novartis receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM)
Approval in newly diagnosed FLT3-mutated AML represents the first new treatment in more than 25 years[1],[2] Rydapt treatment regimen in FLT3-mutated AML demonstrated a significant improvement… -
Media Release
Alcon announces EU launch of CyPass® Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma
Now available in the UK, Germany, Italy and Spain, CyPass Micro-Stent is designed to significantly reduce intraocular pressure (IOP) CE indication has been expanded to allow patients to be… -
Media Release
Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
Net sales grew 2% (cc, -1% USD), as growth drivers more than offset Gleevec/Glivec impact Cosentyx (USD 410 million, +136% cc) showing strong growth in all three indications Entresto (USD 84… -
Media Release
Novartis: ventes en progression (tcc1) dans toutes ses divisions; les moteurs de croissance, Cosentyx et Entresto inclus, compensent l'érosion due aux génériques; l'innovation toujours en plein essor
Chiffre d'affaires net en hausse de 2% (tcc, -1% en USD), car les moteurs de croissance ont plus que compensé l'impact de Gleevec/Glivec Cosentyx (USD 410 millions, +136% tcc):…
Pagination
- ‹ Previous page
- 1
- …
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- …
- 102
- › Next page